Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study
The Journal of Pathology: Clinical Research · 2026-03 · 12 (2)
DOI: 10.1002/2056-4538.70079 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 04.03.2026. Verfasst von Alex Jenei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Experimental Cancer Research, Semmelweis University, Faculty of Medicine, Budapest, Hungary. Hauptthemen laut MEDLINE: Sarcoma, Myeloid, Mutation, Nuclear Proteins, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Myeloid sarcoma (MS) is a tumorous extramedullary proliferation of blast or blast equivalent cells (e.g., promonocytes or promyelocytes). The most frequent cutaneous presentation is often referred to as leukemia cutis (LC). These lesions, especially without the clinical context of a known bone marrow disease, pose a differential diagnostic challenge. In this retrospective multicenter clinico‐pathological study on 154 patients with MS or LC, 169 samples were analyzed by morphology, immunohistochemistry, and fluorescent in situ hybridization, and a subset by additional sequencing [ TP53 ]. The majority of cases were lysozyme positive (diffuse in 91% and focal in 5%), 51% showed diffuse and 6% focal expression of CD56, and IRF8 was strongly positive in 31% of the lesions. Lack of myeloperoxidase (MPO), CD117, and CD34 expression was observed in 27%, 39%, and 58%, respectively. PU.1 was positive in almost all instances (95%), but BRAF V600E was consistently negative. CD123 was diffusely (13%) or focally (25%) positive, which, in addition to frequent CD4 (73%) and CD56 expression, pointed to a phenotypic overlap with blastic plasmacytoid dendritic cell neoplasms. Survival analysis revealed that MS occurring at sanctuary sites (CNS, orbit, ovary, and testis) was characterized by excellent survival. Similarly to histiocytoses, there was a prognostic difference between isolated and multisystemic involvement by MS. Patients who underwent allogeneic hematopoietic stem cell transplantation showed significantly improved survival. In conclusion, this multicenter study suggests that most MS are of myelomonocytic/monoblastic origin, a high proportion of them are NPM1 mutated, and may lack expression of MPO and CD34. NPM1 mutation‐specific antibodies should be integrated into the diagnostic panels for MS or LC, while IRF8 and PU.1 are not recommended as they cannot distinguish MS from histiocytic neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Faculty of Medicine, Budapest, Hungary.
- Department of Pathology, University of Pécs Medical School, Clinical Centre, Pécs, Hungary.
- Histological Diagnostics, Kempf and Pfaltz, Zurich, Switzerland.
- Ekvimed Healthcare Service Ltd., Budapest, Hungary.
- Department of Hematology, University Hospital Basel, Basel, Switzerland.
- Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
ORCID-Profile: Béla Kajtár, Hazem A Juratli, Ágota Szepesi, Botond Timár, Jörg Halter, Stefan Dirnhofer, Alexandar Tzankov
Zitieren
APA
Jenei, A., Kajtár, B., László, T., Juratli, H. A., Vida, L., Szepesi, Á., Mózes, R., Timár, B., Halter, J., Dirnhofer, S., & Tzankov, A. (2026). Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study. The Journal of Pathology: Clinical Research, 12(2). https://doi.org/10.1002/2056-4538.70079
Vancouver
Jenei A, Kajtár B, László T, Juratli HA, Vida L, Szepesi Á, et al. Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study. The Journal of Pathology: Clinical Research. 2026;12(2). doi:10.1002/2056-4538.70079
BibTeX
@article{Jenei2026,
author = {Jenei, Alex and Kajtár, Béla and László, Tamás and Juratli, Hazem A and Vida, Livia and Szepesi, Ágota and Mózes, Réka and Timár, Botond and Halter, Jörg and Dirnhofer, Stefan and Tzankov, Alexandar},
title = {Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study},
journal = {The Journal of Pathology: Clinical Research},
year = {2026},
volume = {12},
number = {2},
doi = {10.1002/2056-4538.70079}
}
EUVIMED